sgrna raav9 vectors (Audentes Therapeutics)
90
Structured Review
Audentes Therapeutics
sgrna raav9 vectors
Sgrna Raav9 Vectors, supplied by Audentes Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgrna+vector/sgrna+raav9+vectors/pm36634841-157-37-1
Average 90 stars, based on 1 article reviews
Sgrna Raav9 Vectors, supplied by Audentes Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgrna+vector/sgrna+raav9+vectors/pm36634841-157-37-1
Average 90 stars, based on 1 article reviews
sgrna raav9 vectors - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Bioprocessing:Article Title: The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Article Snippet: .. Sponsor: Audentes [71,72] AAV-CRISPR-SaCas9 (genome engineering) Preclinical proof of concept In vivo genome editing for DM1: deletion of CTG repeat tract leading to reduction of nuclear foci in muscle fibers after intramuscular injection of SaCas 9 and In Vivo:Article Title: The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Article Snippet: .. Sponsor: Audentes [71,72] AAV-CRISPR-SaCas9 (genome engineering) Preclinical proof of concept In vivo genome editing for DM1: deletion of CTG repeat tract leading to reduction of nuclear foci in muscle fibers after intramuscular injection of SaCas 9 and Injection:Article Title: The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Article Snippet: .. Sponsor: Audentes [71,72] AAV-CRISPR-SaCas9 (genome engineering) Preclinical proof of concept In vivo genome editing for DM1: deletion of CTG repeat tract leading to reduction of nuclear foci in muscle fibers after intramuscular injection of SaCas 9 and |